Selected Reads

Smartkarma

Equity Bottom-Up

Commercial Products: Dextenza; Delayed release steroid inserted in the tear ducts to reduce post-surgical ocular inflammation and pain (often used post cataract surgery) and as a treatment for eye itching...<a target="_blank" href="https://www.valueinvestorsclub.com/idea/OCULAR_THERAPEUTIX_INC/8078753244">Read the article on Value Investor Club »</a>

United States

Ocular Therapeutix, Inc. develops and markets eye care products. The Company offers ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet and underserved needs in ophthalmology. Ocular Therapeutix serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00